Generalized Anxious Disorders
Conditions
Keywords
Generalized anxious disorders, Thermal cure, paroxetine
Brief summary
Multicenter study comparing paroxetine (n=30) versus thermal cure (n=30) in patients with a diagnosis of Generalised Anxiety Disorders
Detailed description
Multicenter study comparing paroxetine (n=30) versus thermal cure (n=30) in patients with a diagnosis of Generalised Anxiety Disorders Main objective is to quantify the therapeutic benefit of a thermal cure on generalized anxiety disorders and to understand the psycho-biological substrates of this improvement. Secondary objectives: * A decrease of Insula activity at rest during the answers to aversive pictures and during the task of subjective measurement of heartbeat. * A decrease of sensibility to emotional interference by subliminal presentation of emotional words thanks to a lexical task and a color recognition task associated to simultaneous measurement of physiological indicator of emotional activity ( dermal resistance)
Interventions
Deroxat® (20 mg/day) 3 week; can be increase on week 2 until 50 mg.
Thermal cure is realized for 3 weeks
Sponsors
Study design
Eligibility
Inclusion criteria
* Diagnostic of generalized anxiety disorder according to the Diagnostic and Statistical Manual of Mental Disorders (DSM IV) * No treatment by antidepressant for at least 2 months * No treatment by anxiolytic/neuroleptic/bete blockers/antipsychotic for at least 3 weeks * Global score of Hamilton Anxiety Scale (HAM-A) is greater or equal to 20 * Score of HAM-A symptoms greater or equal to 8 * Score of Hamilton Depressive Scale (HAM-D) lower or equal to 7 * Age: Participants will be males and females, 18-75 years of age included. * For women, no ongoing pregnancy/ negative pregnancy test * No wounds * Affiliation to a social security system (recipient or assignee) * Signed written inform consent form
Exclusion criteria
* Treatment by antidepressant for at least 2 months or a treatment by anxiolytic, neuroleptic for at least 3 weeks * Psychotropic treatment (antidepressant, anxiolytic and neuroleptic) between the preinclusion and inclusion * Psychotherapy during the 3 months prior to the inclusion * Thermal cure during the 6 months prior to the inclusion * Treatment by paroxetine for at least 1 month with dose equal or superior to 20 mg per day during the 12 months prior to the inclusion * Contraindication to paroxetine * Enhanced protection (minors, pregnancies women, nursing women,people deprived of liberty by administrative or judicial decision, ...) * Blood donation during the 3 months prior to the inclusion
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Decrease Insula activity during a resting state task | The evaluation of primary end point is performed between day 1 and day 24 |
Secondary
| Measure | Time frame |
|---|---|
| Sensibility non conscientious to emotional interference in lexical task and in color identification task | D= Day D1/D24/D56 |
| Modulation of electrodermal response during presentation of predictive stimuli on aversive images and its links to the subjective view of emotional state | D= Day D24 |
| Modulation of electrodermal response during presentation of predictive stimuli on aversive images and insula activation | D= Day D24 |
| Changes of HAM-A score between day 1 and day 24. | The evaluation of primary end point is performed between day 1 and day 24 |
| Evolution (Day 1 and Day 24) of the correlation between HAM-A global score and 1- the measure of heartbeat 2- emotional reactivity during aversive images task. | D= Day D1/D24. |
| Difference (Day 1 and Day 24) of correlations between the symptoms severity and the activation of insula cortex during 1-aversive images task, 2-heartbeat measure task. | D= Day D1/D24. |
| Evaluation of efficacy of the thermal cure Day 56 using HAM-A score | D= Day D56 |
| Lost of significant correlation (Day 24) between HAM-A score, introspective acuity and insula hyperactivation | D= Day D24 |
Countries
France